InMed Pharmaceuticals

11/24/2025

What is neuritogenesis?

In this video, InMed’s CEO, Eric A. Adams, explains the neuritogenesis process and how this process is essential for neuronal signaling and healthy brain functioning.

Video here: https://www.inmedpharma.com/learn/what-is-neuritogenesis-how-does-neuritogenesis-affect-alzheimers-disease/

$INM

In this video, InMed's CEO, Eric A. Adams, explains the neuritogenesis process and how this process is essential for neuronal signaling and healthy brain functioning.

11/21/2025

InMed has conducted several in vitro and in vivo studies to test the pharmacological effects of INM-901 in Alzheimer’s disease preclinical models with promising results demonstrating disease-modifying effects.

A summary of INM-901 preclinical study results:

➡️ Demonstrates neuroprotective effects by reducing cell death in an amyloid-beta-induced cytotoxicity study
➡️ Demonstrates significant reduction in inflammatory biomarkers associated with Alzheimer’s, including IFN-γ, TNF-α, IL-1β, KC-GRO, IL-2 & NfL
➡️ May have a direct impact on neuroinflammation independent of the influence of amyloid beta or tau aggregation
➡️ Demonstrates an ability to promote neurite outgrowth, signifying the potential to improve neuronal function, a potential breakthrough in the treatment of Alzheimer’s disease
➡️ Demonstrates a trend in improvement in cognitive function and memory, locomotor activity, anxiety-based behavior, sound awareness and neuronal function
➡️ Demonstrates robust bioavailability in in vivo models, achieving what is anticipated to be therapeutic levels of systemic exposure
➡️ Additional mRNA data supports the observations made in behavior studies in locomotor activity, cognition and memory.

More about InMed's INM-901 program here: https://www.inmedpharma.com/pharmaceutical/inm-901-for-alzheimers-disease/

$INM

11/20/2025

Webinar Replay: Alzheimer’s Outlook – Neuroinflammation, the Next Step

Alzheimer’s disease research experts come together for this informative session. Learn about:

-Role of neuroinflammation in the development of cognition-impairing disease
-Biological pathways to developing drugs to address neuroinflammation
-Why neuroinflammation is an important target for novel Alzheimer’s treatments
-Importance of patient diversity in clinical trial design
-Scanning the horizon – what to expect in the next 5 years

Watch Fierce Biotech webinar here: https://ow.ly/WV4C50XurIP

$INM

Fierce Biotech Webinar “Alzheimer’s Outlook – Neuroinflammation, the Next Step” is now available on demand. InMed’s Senior VP, Preclinical Research and Development, Dr. Eric Hsu, joins a panel of experts to speak about recent breakthroughs in Alzheimer’s disease research and the effects ...

11/19/2025

Fierce Biotech Article: Neuroinflammation a Key Underlying Factor in Alzheimer’s Disease Risk

Several studies presented at the AAIC 2025 conference investigated the correlation between inflammatory biomarkers and the risk of Alzheimer’s disease and other dementias. Researchers are turning their attention to how inflammation influences cognitive decline.

Article here: https://ow.ly/FxNU50XtJkb

$INM

Article featured in Fierce Biotech October 16, 2025 Excerpt: New findings discussed at the latest Alzheimer’s Association International Conference (AAIC) highlight the risk factors associated with Alzheimer’s disease. Amongst the risks are inflammation-related factors. What is new research telli...

11/18/2025

InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901.

This marks the first preclinical study in which the oral formulation of INM-901 was administered in large animals. The results provide additional data in guiding decisions in the design of a human Phase 1 clinical trial program.

Read news release: https://ow.ly/yXuC50XtJqz

$INM

11/18/2025

InMed today announced the successful completion of pharmacokinetic studies in large animal models for its Alzheimer’s disease candidate INM-901.

Dr. Eric Hsu, Senior VP, Preclinical R&D commented, “The successful completion of our first large animal PK study is very encouraging for the INM-901 program. The data supports the clinical applicability of our INM-901 oral formulation and provides important insights as we plan and design our IND-enabling studies and Phase 1 clinical trials. Furthermore, the neurological assessments strengthen our confidence in the compound’s overall safety profile.”

Read news release: https://ow.ly/GCRO50Xtfhs

$INM

11/18/2025

InMed Completes Pharmacokinetic Studies in Large Animal Model for its Alzheimer’s Disease Candidate INM-901

This marks the first preclinical study in which the oral formulation of INM-901 was administered in large animals. The results provide additional data in guiding decisions in the design of a human Phase 1 clinical trial program.

Read full news release here: https://ow.ly/3kT350XtffS

$INM

11/18/2025

: InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for its Alzheimer’s Disease Candidate INM-901

Read full news release here: https://ow.ly/VPP450XteSy

$INM

11/17/2025

InMed's INM-901 demonstrates a reduction in markers associated with Disease. The preclinical results were shared in a poster presentation at the AAIC conference.

Read the poster here: https://ow.ly/B4Nv50Xt4Li

$INM

InMed presented data from its INM-901 Alzheimer’s disease program at the 2025 Alzheimer’s Association International Conference held in Toronto, Canada. The latest study presented in a scientific poster entitled, “Therapeutic Potential of INM-901 in Mitigating Alzheimer’s Disease Pathology: I...

11/06/2025

InMed Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update.

CEO Eric Adams, "Fiscal 2026 is shaping up to be another strong year for InMed as we advance our lead program INM-901 toward clinical readiness. INM-901 continues to demonstrate compelling data across multiple preclinical models, reinforcing its potential as a differentiated small-molecule therapy targeting Alzheimer’s disease. With IND-enabling activities advancing, we are entering an important stage in translating INM-901’s scientific promise into clinical evaluation."

Read full news release here: https://ow.ly/3Ryz50Xo6OV

$INM

11/06/2025

: InMed Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update

Read full news release here: https://ow.ly/xryI50Xo6MG

$INM

11/05/2025

Several studies presented at the AAIC 2025 conference investigated the correlation between inflammatory biomarkers and the risk of Alzheimer’s disease and other dementias. Researchers are turning their attention to how inflammation influences cognitive decline.

More here in this article: https://ow.ly/2PPt50Xnm6h

$INM

| AAIC 2025 spotlights inflammation in Alzheimer’s; InMed’s INM-901 reduces key biomarkers linked to disease progression